This article has Open Peer Review reports available.
Influence of ischemia before vein grafting on early hyperplasia of the graft and the dynamic changes of the intima after grafting
© Zou et al.; licensee BioMed Central Ltd. 2012
Received: 3 February 2012
Accepted: 20 September 2012
Published: 24 September 2012
To investigate both the influence of ischemia before grafting on early hyperplasia of the vein grafts, and the dynamic changes of the intima after grafting in a rabbit model of vein graft disease.
We performed paired vein graft experiments under different ischemic conditions (15 vs. 60 min; 15 vs. 90 min) in the neck of the rabbits and compared the differences between the grafts. Clopidogrel, an anti-platelet agent, was administered before and after surgery. Twenty-eight days after the grafting procedure, the veins were evaluated microscopically. The dynamic changes of the intima after grafting were evaluated by scanning electron microscopy over time.
The vein grafts subjected to 60- or 90-min ischemia exhibited no differences compared to those subjected to 15-min ischemia in terms of the mean thickness of the intimal, medial, and adventitial layers of the graft. Similarly, there was no difference in the Ki-67 labeling index (proliferation marker) between the vein grafts. Vein grafts with 15-min ischemia lost endothelial cells (ECs) but healed by 3 days post graft, whereas vein grafts with 90-min ischemia suffered serious EC loss, which was restored with new ECs during days 2 to 14 post graft.
Ninety-minute ischemia before vein grafting can cause serious EC loss, but does not increase early intimal hyperplasia when clopidogrel is administered. Protecting the vein from ischemia and reperfusion injury preserves ECs.
The autologous saphenous vein is the most common conduit for coronary artery bypass grafting (CABG), despite of increased use of arterial grafts in cardiac surgery. After grafting, this vein is subjected to immediate increases in flow, resulting in longitudinal wall shear stress, circumferential deformation, and pulsatile stress. This can cause intimal hyperplasia and progressive thickening of the vein graft wall to occur. Approximately 60% of vein grafts remain patent long term, of which only 50% are free of significant stenosis[1–3].
Endothelial cell (EC) injury plays a significant role in acute thrombosis after vein grafting. Heparinized autologous blood and other solutions are typically used before grafting to protect the endothelium and its functions[5–7]. Another method for reducing acute thrombosis after grafting is the use of anti-platelet drugs to reduce the risk of thrombosis. Such drugs have been demonstrated to improve graft patency and have been used routinely post operation. When the risk of acute of thrombosis is reduced by such means, influence of ischemia before vein grafting on early hyperplasia of the graft can be studied to find out the ischemic time not increasing the hyperplasia under different preservation. In this study, we designed a series of paired trials to evaluate the effects of different ischemic times on hyperplasia associated with vein grafts when clopidogrel, an anti-platelet agent, was used.
Animals and grouping
New Zealand white rabbits weighed between 2.5 and 3.0 kg were raised and provided by the Laboratory Animal Center of Shanghai No. 6 People's Hospital. The protocol for animal experiments was approved by the Committee of Ethics on Animal Experiments at the Shanghai Jiao Tong University School of Medicine, based on the Guidelines for Animal Experiments. The rabbits were randomly divided into two groups: (1) 15- vs. 60-min ischemia and (2) 15- vs. 90-min ischemia.
Vein graft surgery
Anesthesia was induced in the rabbits with intravenous ethaminal sodium (15 to 30 mg/kg, depending on the response of the rabbit to the drug), allowing spontaneous ventilation throughout the procedure. In addition, heparin sodium (250 U/kg) and penicillin (400 kU) were administered intravenously before creating a skin incision. In each animal, a longitudinal incision was made in the neck over the region of the internal jugular vein. The internal jugular vein and the common carotid artery were dissected using the “no touch” technique, and the side branches were ligated with 5–0 silk sutures.
After 4 weeks, the grafts, each including a 0.5-cm segment of the proximal and distal common carotid artery, were harvested from the rabbits under anesthesia. The grafts were rinsed in saline and the vessel lumen was infused with 10% formalin at a pressure of 100 mmHg, simulating the systolic pressure for 12 h. Each of the grafts was divided into three equal parts. Each part was dehydrated, cleared, and paraffin-embedded. Approximately 5-μm transverse sections were taken from three points in each graft, mounted onto glass slides, and stained with hematoxylin/eosin (H/E) and Ponceau Red/Victoria Blue (P/VB).
To evaluate the influence of the infusion pressure on the intima by scanning electron microscopy (SEM), two sides of the ungrafted internal jugular veins were removed from 2 rabbits. After being rinsed in saline, the veins of one side were preserved in 2.5% glutaraldehyde (SIGMA, St. Louis, MO) for 12 h, and the veins of the other side were infused intraluminally with 2.5% glutaraldehyde at a pressure of 100 mmHg for 12 h. All veins were bisected and secured on a cork mounting board with 8–0 polypropylene sutures.
To observe dynamic changes in the intima by SEM, an additional 15- vs. 90-min ischemia group was also studied. Grafts were harvested at 1 h, and 1, 2, 3, 7, 14, and 28 days after grafting (2 rabbits at each time point). These grafts were rinsed in saline and infused intraluminally with 2.5% glutaraldehyde at a pressure of 100 mmHg for 12 h. Subsequently, the grafts were bisected and secured on a cork mounting board with 8–0 polypropylene sutures.
The vessel wall dimensions were captured under an LW200T light microscope (Shanghai Cewei Photoelectric Technology Co. Ltd., Shanghai, China) with a color video camera head (DH-HV3103UCUSB; Daheng Group, Inc., Beijing, China) and measured with YRMV image-analysis software (Shanghai Yinrui Information Technology Co. Ltd., Shanghai, China). The mean intimal, medial, and adventitial thickness measurements were derived by measuring the areas and perimeters of the borders between the intimal and medial sections of each graft.
Immunocytochemistry and cell proliferation analysis
Cell proliferation was detected with immunohistochemistry using Ki-67 via a 3-step staining procedure. Briefly, 5-μm-thick sections were cut from all paraffin-embedded tissue samples, placed onto slides, dewaxed, and hydrated in graded alcohols. Microwave pretreatment with BD Retrievagen A (pH 6.5) (BD Biosciences, San Diego, CA) for 10 min was performed, and slides were left to cool for 30 min before being rinsed in 0.05 mol/L Tris-buffered saline (TBS). Sections were then incubated with rabbit serum for 30 min, followed by a 1-h incubation with mouse monoclonal antibody against Ki-67 (B56; BD Biosciences). Subsequently, sections were treated with a secondary biotinylated goat anti-mouse antibody (DAKO, Glostrup, Denmark) for 10 min. TBS was used as a washing buffer between the antibody incubation steps. The samples were then incubated with streptavidin-HRP (DAKO, Glostrup, Demmark) for 10 min and 0.05% 3,3-diaminobenzidine (DAB) for 10 min. A light counter stain with hematoxylin (30 sec) was applied to permit visualization of morphology.
In each tissue section, the total number of cells and the number of Ki-67-positive cells were counted in the intima, media, and adventitia in 6 microscopic fields of view with a 40× objective. The labeling index was calculated as the percentage of positive nuclei.
Scanning electron microscopy
Samples were fixed in 2.5% glutaraldehyde, rinsed in 0.1 M phosphate buffer, fixed in 1% osmic acid (4°C for 2 h), and dehydrated through a graded series of ethanol (50% to 100%) and amyl acetate. The samples were critical point-dried (HCP-2; Hitachi, Tokyo, Japan), sputter coated with a thin layer of gold (IB-3; Eiko Engineering, Ibataki, Japan), and analyzed with SEM (S-520; Hitachi).
All data were analyzed using SPSS 12.0 for Windows, and are expressed as the mean ± standard deviation (SD). A comparison between veins with different ischemic times in each group was performed using the paired Student’s t-test. P-values less than 0.05 were considered statistically significant.
All grafts remained patent after operation, and no cases of grossly visible thrombus or mural thrombus occurred. The grafts were adherent to surrounding tissues, and some regions were seemingly well incorporated.
Comparison of vein grafts under different ischemic conditions
Thickness of graft layers (μm)
50 ± 13
45 ± 6
54 ± 10
62 ± 21
51 ± 8
40 ± 13
52 ± 3
52 ± 10
219 ± 39
188 ± 52
183 ± 23
253 ± 61
Immunocytochemistry and cell proliferation analysis
Scanning electron microscopy observation of intima
Ischemic injury before grafting and reperfusion injury after grafting may injure ECs, and subsequently activate platelets and trigger the coagulation cascade. Various solutions and heparinized autologous blood have been used previously for vein preservation to reduce ischemia and reperfusion (IR) injury. For instance, Cavallari et al. used autologous whole blood (AWB), 0.9% normal saline solution (NS), and University of Wisconsin solution (UWs) individually to treat autogenous vein grafts for 45 min at 4°C before grafting, and found the veins stored in UWs had a similar intimal thickness with that of control samples, whereas the veins stored in AWB or NS had a thicker intima layer after grafting. However, Solberg et al. found that veins stored in cell culture media at 4°C show a marked increase in EC dysjunction and an 18% loss of EC number, compared to only a 4% loss at 20°C, indicating that hypothermy may injure ECs. In typical situations, the veins are placed in saline containing heparin sodium at 20°C after being removed. Therefore, we designed this study to investigate the influence of pre-grafting ischemia on early hyperplasia after grafting under these conditions, and found the ischemic tolerance of the vein. After the step, we planed to investigate how long the veins can be preserved in the solutions (such as UWs) or how long the AWB should be renewed. The cuff technique was used in this study for the vein graft model because it can limit the ischemic time caused by the procedure to 15 min, avoiding IR injury. In one side, the veins were grafted immediately after removal to offer controls, whereas, in the other side, the veins were stored before being used. We also included clopidogrel treatment to reduce the risk of thrombus or mural thrombus and to make the vein graft model more similar to the clinical situation.
Prospective controlled trials have demonstrated a graft patency benefit when aspirin was started 1, 7, or 24 h postoperatively, a benefit which was lost when started after 48 h. Aspirin has been shown to significantly reduce postoperative mortality, myocardial infarction, stroke, renal failure, and bowel infarction when administered within 48 h of CABG. However, in patients with atherosclerotic vascular disease, clopidogrel is more effective than aspirin in reducing the combined risk of stroke, myocardial infarction, and vascular death.
Besides having anti-thrombotic properties, inhibitors of platelet aggregation attenuate platelet function, prevent platelet activation and release of peptide growth factors and nonpeptide substances, and thereby inhibit intimal hyperplasia. Atherosclerosis is described as an inflammatory disease. Clopidogrel inhibits the expression of platelet activation markers and the interaction of platelets and leukocytes, and is powerful in decreasing the levels of inflammatory factors.
In our present study, SEM revealed that 90-min ischemia caused serious injury of the intima, including the exposed subendothelial collagen fibers that may aggregate and activate platelets and the frequently adherent leukocytes, which may trigger vascular inflammation. Clopidogrel was used and avoided thrombus or mural thrombus successfully. Moreover, results show no differences between vein grafts with 15- and 60-min ischemia or 15- and 90-min ischemia in term of thickness and the hyperplasia intensity of the intima, media, or adventitia at 4 weeks after the grafting procedure. It seems ischemia up to 90 min does not increase early intimal hyperplasia of the vein graft when clopidogrel was used effectively. Approximately 90 min is a long enough time period for surgeons to complete 3 or 4 bypasses; therefore, when using clopidogrel, it is seemingly unnecessary to consider the influence of ischemia before grafting on early hyperplasia of the vein grafts.
The recovery of the intima was also observed post operation. EC coverage has been used in some studies[18, 19], which is easily gained and facilitates statistical analysis. However, based on our study, it is apparently unreliable because fibrin and micro thrombi covered the surface of the intima when there was IR injury according to SEM analysis. Therefore, we only reported the characteristics of the intima in this study.
According to our observations, the intimae of vein grafts with 15-min ischemia only lost a portion of their ECs and reintegrated at 3 days post operation. However, the intimae of vein grafts with 90-min ischemia lost all their ECs and redintegrated at 14 days post operation. Furthermore, the anterior had less risk of thrombosis. Reducing ischemia and reperfusion injury is valuable. It has been suggested previously that UWs preserves the vein before grafting because of its excellent effect on protecting the endothelium and its functions.
However, vein grafts with 15-min ischemia, which had almost no IR injury, likely face a widely torn intima caused by systolic pressure 1 h after grafting. Furthermore, the vein grafts with 90-min ischemia likely face more serious loss of ECs until new ECs are present, which come predominantly from extrinsic cells such as bone marrow-derived cells, and form an intima layer with integrity. Thus, it seems antithrombotic therapy should be administered as early as possible post operation.
Gavaghan et al. found that administering aspirin within 1 h of CABG did not increase chest-tube blood loss, the red cell transfusion requirements, or the re-exploration rate. However, Goldman et al. reported that aspirin use on the day before CABG has a similar effect on early graft patency within 6 h after surgery, and increased bleeding complications. Considering that the number of platelets and the levels of blood coagulation factors vary and change with time after CABG, we recommend starting anti-platelet therapy when the postoperative chest tube drainage is ≤50 ml/h for 2 consecutive hours, as presented by both Halkos et al. and Chan et al.[24, 25].
In summary, our study indicates that, when clopidogrel is administered effectively, ischemia up to 90 min does not increase early intimal hyperplasia of the vein grafts, although a long-term study is necessary for information on later time points after operation. Furthermore, IR injury can cause serious EC loss, avoiding the injury preserves ECs.
- Bourassa MG: Fate of venous grafts: the past, the present, and the future. J Am Coll Cardiol. 1991, 5: 1081-1083.View ArticleGoogle Scholar
- Fitzgibbon GM, Kafka HP, Leach AJ, Keon WJ, Hooper GD, Burton JR: Coronary bypass graft fate and patient outcome: angiographic follow-up of 5065 grafts related to survival and reoperation in 1388 patients during 25 years. J Am Coll Cardiol. 1996, 28: 616-626.View ArticlePubMedGoogle Scholar
- Campeau L, Enjalbert M, Lespérance J, Bourassa MG, Kwiterovich P, Wacholder S, Sniderman A: The relation risk factor to the development of atherosclerosis in saphenous vein bypass grafts and the progression of disease in the native circulation: a study 10 years after aortocoronary bypass surgery. N Engl J Med. 1984, 311: 1329-1332. 10.1056/NEJM198411223112101.View ArticlePubMedGoogle Scholar
- Motwani J, Topol E: Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. Circulation. 1998, 97: 916-931. 10.1161/01.CIR.97.9.916.View ArticlePubMedGoogle Scholar
- Thatte HS, Biswas KS, Najjar SF, Birjiniuk V, Crittenden MD, Michel T, Khuri SF: Multi-photon microscopic evaluation of saphenous vein endothelium and its preservation with a new solution, GALA. Ann Thorac Surg. 2003, 75: 1145-1152. 10.1016/S0003-4975(02)04705-7.View ArticlePubMedGoogle Scholar
- Sakaguchi T, Asai T, Belov D, Okada M, Pinsky DJ, Schmidt AM, Naka Y: Influence of ischemic injury on vein graft remodeling: role of cyclic adenosine monophosphate second messenger pathway in enhanced vein graft preservation. J Thorac Cardiovasc Surg. 2005, 129: 129-137. 10.1016/j.jtcvs.2004.04.014.View ArticlePubMedGoogle Scholar
- Souza DSR, Johansson B, Bojö L, Karlsson R, Geijer H, Filbey D, Bodin L, Arbeus M, Dashwood MR: Harvesting the saphenous vein with surrounding tissue for CABG provides long-term patency comparable to the left internal thoracic artery: results of a randomised longitudinal trial. J Thorac Cardiovasc Surg. 2006, 132: 373-378. 10.1016/j.jtcvs.2006.04.002.View ArticlePubMedGoogle Scholar
- Mangano DT, For the Multicenter Study of Perioperative Ischemia Research Group: Aspirin and mortality from coronary bypass surgery. N Engl J Med. 2002, 347: 1309-1317. 10.1056/NEJMoa020798.View ArticlePubMedGoogle Scholar
- Eagle KA, Guyton RA, Davidoff R, Edwards FH, Ewy GA, Gardner TJ, Hart JC, Herrmann HC, Hillis LD, Hutter AM, Lytle BW, Marlow RA, Nugent WC, Orszulak TA, Antman EM, Smith SC, Alpert JS, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Gregoratos G, Halperin JL, Hiratzka LF, Hunt SA, Jacobs AK, Ornato JP: American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American Society for Thoracic Surgery and the Society of Thoracic Surgeons. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). Circulation. 1999, 110: 1168-1176.View ArticleGoogle Scholar
- Shuhaiber JH, Evans AN, Massad MG, Geha AS: Mechanisms and future directions for prevention of vein graft failure in coronary bypass surgery. Eur J Cardiothorac Surg. 2002, 22: 387-396. 10.1016/S1010-7940(02)00253-1.View ArticlePubMedGoogle Scholar
- Cavallari N, Abebe W, Mingoli A, Sapienza P, Hunter WJ, Agrawal DK, Cavallaro A, Edwards JD: Short-term preservation of autogenous vein grafts: effectiveness of University of Wisconsin solution. Surgery. 1997, 121: 64-71. 10.1016/S0039-6060(97)90184-7.View ArticlePubMedGoogle Scholar
- Solberg S, Larsen T, Jørgensen L, Sørlie D: Cold-induced endothelial cell detachment in human saphenous vein grafts. J Cardiovasc Surg. 1987, 28: 571-575.Google Scholar
- CAPRIE Steering Committee: A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996, 348: 1329-1339.View ArticleGoogle Scholar
- Anderson HV, McNatt J, Clubb FJ, Herman M, Maffrand JP, DeClerck F, Ahn C, Buja LM, Willerson JT: Platelet Inhibition Reduces Cyclic Flow Variations and Neointimal Proliferation in Normal and Hypercholesterolemic-Atherosclerotic Canine Coronary Arteries. Circulation. 2001, 104: 2331-2337. 10.1161/hc4401.098434.View ArticlePubMedGoogle Scholar
- Ross R: Atherosclerosis—an inflammatory disease. N Engl J Med. 1999, 340: 115-126. 10.1056/NEJM199901143400207.View ArticlePubMedGoogle Scholar
- Graff J, Harder S, Wahl O, Scheuermann EH, Gossmann J: Anti-inflammatory effects of clopidogrel intake in renal transplant patients: effects on platelet-leukocyte interactions, platelet CD40 ligand expression, and proinflammatory biomarkers. Clin Pharmacol Ther. 2005, 78: 232-241. 10.1016/j.clpt.2005.06.002.View ArticleGoogle Scholar
- Li M, Zhang Y, Ren H, Zhang Y, Zhu X: Effect of clopidogrel on the inflammatory progression of early atherosclerosis in rabbits model. Atherosclerosis. 2007, 194: 348-356. 10.1016/j.atherosclerosis.2006.11.006.View ArticlePubMedGoogle Scholar
- Ishikawa M, Sasajima T, Kubo Y: Re-endothelialisation in autogenous vein Grafts. Eur J Vasc Endovasc Surg. 1996, 11: 105-111. 10.1016/S1078-5884(96)80143-2.View ArticlePubMedGoogle Scholar
- Ehsan A, Mann MJ, Dell'Acqua G, Tamura K, Braun-Dullaeus R, Dzau VJ: Endothelial Healing in Vein Grafts: Proliferative Burst Unimpaired by Genetic Therapy of Neointimal Disease. Circulation. 2002, 105: 1686-1692. 10.1161/01.CIR.0000013775.02396.93.View ArticlePubMedGoogle Scholar
- Barner HB, Fischer VW: Endothelial preservation in human saphenous veins harvested for coronary grafting. J Thorac Cardiovasc Surg. 1990, 10: 148-149.Google Scholar
- Zhang L, Freedman NJ, Brian L, Peppel K: Graft-Extrinsic Cells Predominate in Vein Graft Arterialization. Arterioscler Thromb Vasc Biol. 2004, 24: 470-476. 10.1161/01.ATV.0000116865.98067.31.View ArticlePubMedGoogle Scholar
- Goldman S, Copeland J, Moritz T, Henderson W, Zadina K, Ovitt T, Kern KB, Sethi G, Sharma GV, Khuri S: Starting aspirin therapy after operation. Effects on early graft patency. Department of Veterans Affairs Cooperative Study Group. Circulation. 1991, 84: 520-552. 10.1161/01.CIR.84.2.520.View ArticlePubMedGoogle Scholar
- Gavaghan TP, Gebski V, Baron DW: Immediate postoperative aspirin improves vein graft patency early and late after coronary artery bypass graft surgery. A placebo-controlled, randomized study. Circulation. 1991, 83: 1526-1533. 10.1161/01.CIR.83.5.1526.View ArticlePubMedGoogle Scholar
- Halkos ME, Cooper WA, Petersen R, Puskas JD, Lattouf OM, Craver JM, Guyton RA: Early administration of clopidogrel is safe after off-pump coronary artery bypass surgery. Ann Thorac Surg. 2006, 81: 815-819. 10.1016/j.athoracsur.2005.08.056.View ArticlePubMedGoogle Scholar
- Chan V, Kulik A, Bourke ME, Ressler L, Mesana TG, Ruel M: Clopidogrel is safe early after on- and off-pump coronary artery bypass surgery. J Card Surg. 2007, 22: 493-497. 10.1111/j.1540-8191.2007.00475.x.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.